Effect of weak electromagnetic fields on the amplitude of the pattern reversal VEP response in Parkinson's disease

International Journal of Neuroscience

Volumn 84, Issue 1-4, 1996, Pages 165-175

  Sandyk, Reuven ^a,b,c  

^a NeuroCommunication Res Laboratories   (United States)

^b TOURO COLLEGE   (United States)

^c NONE   (United States)

Author keywords

Amplitude; Dopamine; Electromagnetic fields; Melatonin; Parkinson's disease; Visual evoked potentials (VEP)

Indexed keywords

AGED; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTROMAGNETIC FIELD; EVOKED VISUAL RESPONSE; HUMAN; MALE; MIDDLE AGED; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHOTOSTIMULATION; PHYSIOLOGY; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL;

AGED; ELECTROMAGNETIC FIELDS; EVOKED POTENTIALS, VISUAL; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PHOTIC STIMULATION;

EID: 0030078347     PISSN: 00207454     EISSN: None     Source Type: Journal    
DOI: 10.3109/00207459608987262     Document Type: Article

References (68)

1. Ames, A. & Pollen, L. A. (1969). Neurotransmission in central nervous tissue: a study of isolated rabbit retina. Journal of Neurophysiology, 32, 424-442.
2. 14C dopamine in platelets: evidence for a generalized defect in Parkinson's disease. Neurology, 25, 1-9.
3. Bawin, S. M. & Adey, W. R. (1976). Sensitivity of calcium binding in cerebral tissue to weak environmental electric fields oscillating at low frequency. Proceedings of the National Academy of Sciences, USA, 73, 1999-2003.
4. Bhaskar, P. A., Vanchilingam, S., Bhaskar, A., Devaprabhu, A. & Ganesan, R. A. (1986). Effect of L-dopa on visual evoked potential in patients with Parkinson's disease. Neurology, 36, 1119-1121.
5. Blackman, C. F. (1988). Stimulation of brain tissue in vitro by extremely low frequency, low intensity, sinusoidal electromagnetic fields. In M. E. O'Connor & R. H. Lovely (Eds.), Electromagnetic fields and neurobehavioral function. New York: Alan R. Liss.
6. Bodis-Wollner, I. & Onofrj, M. (1986). The visual system in Parkinson's disease. In M. D. Yahr & K. J. Bergmann (Eds.), Advances in neurology (pp. 323-327). New York: Raven Press.
7. Bodis-Wollner, I., Yahr, M. D. & Thornton, J. (1980). Visual evoked potentials and the severity of Parkinson's disease. In F. C. Rose & R. Capildeo (Eds.), Research progress in parkinson's disease (pp. 126-146). Kent: Pitman Medical.
8. Bodis-Wollner, I., Yahr, M. p., Mylin, L. & Thornton, J. (1982). Dopaminergic deficiency and delayed visual evoked potentials in humans. Annals of Neurology, 11, 478-483.
9. Bradbury, A. J., Kelly, M. E. & Smith, J. A. (1985). Melatonin action in the mid-brain can regulate dopamine function both behaviourally and biochemically. In G. M. Brown & S. D. Wainwright (Eds.), The pineal gland: endocrine aspects (pp. 327-332). Oxford: Pergamon Press.
10. Buchsbaum, M. S., Van Kammen, D. P. & Murphy, D. L. (1977). Individual differences in average evoked responses to d-and l-amphetamine with and without lithium carbonate in depressed patients. Psychopharmacologia, 51, 129-135.
11. Burton, S., Daya, S. & Potgieter, B. (1991). Melatonin modulates apomorphine-induced rotational behaviour. Experientia. 47, 466-469.
12. Cardinali, D. P., Vacas, M. I. & Boyer, E. E. (1979). Specific binding of melatonin in bovine brain. Endocrinology, 105, 437-441.
13. Cotzias, G. C., Tang, L. C., Miller, S. T. & Ginos, J. Z. (1971). Melatonin and abnormal movement induced by L-dopa in mice. Science, 173, 450-452.
14. Cutler, J. R., Aminoff, M. J. & Brant-Zawadzki, M. (1986). Evaluation of patients with multiple sclerosis by evoked potentials and magnetic resonance imaging: a comparative study. Annals of Neurology, 20, 645-648.
15. Dinner, D. S., Luders, H., Hanson, M., Lesser, R. P. & Klem, G. (1985). Pattern evoked potentials (PEPs) in Parkinson's disease. Neurology, 35, 610-613.
16. Dubocovich, M. L. (1983). Melatonin as a potent modulator of dopamine release in the retina. Nature, 306, 782-784.
17. Dyer, R. S., Howell, W. E. & MacPhail, R. C. (1981). Dopamine depletion slows retinal transmission. Experimental Neurology. 71, 326-340.
18. Ehle, A. L., Stewart, R. M., Lellelid, E. & Leventhal, N. A. (1982). Normal checkerboard pattern reversal evoked potentials in parkinsonism. Electroencephalography and Clinical Neurophysiology, 54, 336-338.
19. Frederick, J. M., Rayborn, M. E., Laties, A. M., Lam, D. M. K. & Hollyfield, J. G. (1982). Dopamine neurons in the human retina. Journal of Comparative Neurology, 210, 65-79.
20. Goodwin, F. K., Murphy, D. L., Brodie, H. K. H. & Bunney, W. E. (1970). L-dopa, catecholamines, and behavior: a clinical and biochemical study in depressed patients. Biological Psychiatry, 2, 341-366.
21. Gottfries, C. G., Perris, C. & Roos, B. E. (1974). Visual average evoked responses (AER) and monoamine metabolites in cerebrospinal fluid (CSF). Acta Psychiatrica Scandinavica, 255 (suppl), 135-142.
22. Halliday, A. M. (1978). Clinical applications of evoked potentials. In W. B. Matthews & G. H. Glaser (Eds.), Recent advances in clinical neurology (pp. 47-73). Edinburgh: Churchill Livingstone.
23. Hoehn, M. M. & Yahr, M. D. (1967). Parkinsonism: onset, progression, and mortality. Neurology, 17, 427-442.
24. Holder, G. E., Bartlett, J. R., Bridges, P. K., Kantamanei, B. D. & Curzon, G. (1980). Correlation between transmitter metabolite concentrations in human ventricular cerebrospinal fluid and pattern visual evoked potentials. Brain Research, 188, 582-586.
25. Kadobayashi, I., Mikani, M. & Kato, N. (1976). Inhibition and enhancement of photically evoked responses by different doses of L-dopa. Experientia, 32, 343-345.
26. Karson, C. N., Berman, K. F., Kleinman, J. & Karoum, F. (1984). Seasonal variation in human central dopamine activity. Psychiatry Research. 11, 111-117.
27. Kelly, P. H. (1977). Drug induced motor behavior. In L. L. Iversen, S. D. Iversen & S. H. Snyder (Eds.), Handbook of psychopharmacology, vol. 8 (pp. 295-331). New York: Plenum.
28. Kopp, N., Claustrat, B. & Tappaz, M. (1980). Evidence for the presence of melatonin in the human brain. Neuroscience Letters, 19, 237-242.
29. Laudon, M., Nir, I. & Zisapel, N. (1988). Melatonin receptors in discrete brain areas of the male rat. Impact of aging on density and on circadian rhythmicity. Neuroendocrinology, 48, 577-583.
30. Miledi, R. (1973). Transmitter release induced by injection of calcium ions into nerve terminals. Proceedings of the Royal Society of Biological Sciences, 183, 421-428.
31. Mintz, M., Tomer, R., Radwan, H. & Myslobodsky, M. S. (1981). Visual evoked potentials in hemiparkinsonism. Electroencephalography and Clinical Neurophysiology, 52, 611-616.
32. Niles, L. P., Wong, Y. W., Mishra, R. K. & Brown, G. M. ( 1979). Melatonin receptors in brain. European Journal of Pharmacology. 55, 219-220.
33. Olcese, J. M. (1992). Magnetoreception in rodents: involvement of the eyes and the pineal organ may be evidence for a chronobiological substrate. In M. C. Moore-Ede, S. S. Campbell & R. J. Reiter (Eds.), Electromagnetic fields and circadian rhythmicity (pp. 63-73). Boston: Birkhauser.
34. Onofrj, M. & Bodis-Wollner, I. (1982). Dopaminergic deficiency causes delayed visual evoked potentials in rats. Annals of Neurology, 11, 484-490.
35. Prieto, S., Villar, J. I. & y Bachini, O. (1965). Influencias pharmacologias sobre la respuesta visual provocada en el hombre. Acta Neurologica Latinoamerica, 11, 295-296.
36. Redmond, D. E., Borge, G. F., Buchsbaum, M. & Maas, J. W. (1975). Evoked potential studies of brain catecholamine alterations in monkeys. Journal of Psychiatric Research, 12., 97-116.
37. Reichardt, L. F. & Kelly, R. B. (1983). A molecular description of nerve terminal function. Annual Review of Biochemistry; 52, 871-926.
38. Reiter, R. J. (1992). Changes in circadian melatonin synthesis in the pineal gland of animals exposed to extremely low frequency electromagnetic radiation: A summary of observations and speculation on their implications. In M. C. Moore-Ede, S. S. Campbell & R. J. Reiter (Eds.), Electromagnetic fields and circadian rhythmicity (pp. 13-27). Boston: Birkhauser.
39. Rosen, A. D. (1992). Magnetic field influence on acetylcholine release at the neuromuscular junction. American Journal of Physiology, 262 (cell physiol, 31), C1418-C1422.
40. Rosen, A. D. & Lubowsky, J. (1987). Magnetic fields influence on central nervous system function. Experimental Neurology, 95, 619-687.
41. Saletu, B. (1977). Cerebral evoked potentials in psychopharmacology. Auditory evoked potentials in man. Psychopharmacology correlates of EPs. In J. E. Desmedt (Ed.), Progress in clinical neurophysiology, vol. 2 (pp. 175-207). Basel: Karger.
42. Sallanon, M., Claustrat, B. & Touret, M. (1982). Presence of melatonin in various cat brainstem nuclei determined by radioimmunoassay. Acta Endocrinologica, 101, 161-165.
43. Sandyk, R. (1992 a). Weak magnetic fields as a novel therapeutic modality in Parkinson's disease. International Journal of Neuroscience, 66, 1-15.
44. Sandyk, R. (1992 b). Magnetic fields in the therapy of parkinsonism. International Journal of Neuroscience, 66, 209-235.
45. Sandyk, R. (1992 c). Weak magnetic fields in the treatment of Parkinson's disease with the "on-off" phenomenon. International Journal of Neuroscience, 66, 97-106.
46. Sandyk, R. (1994 a). A drug naive Parkinsonian patient successfully treated with electromagnetic fields. International Journal of Neuroscience, 79, 99-110.
47. Sandyk, R. (1994 b). Reversal of a visuoconstructional deficit in Parkinson's disease by application of external magnetic fields: a report of five cases. International Journal of Neuroscience, 75, 213-228.
48. Sandyk, R. (1994 c). Reversal of visuospatial hemi-inattention in patients with chronic progressive multiple sclerosis by treatment with weak electromagnetic fields. International Journal of Neuroscience, 79, 169-184.
49. Sandyk, R. (1994 d). Treatment of Parkinson's disease with magnetic fields reduces the requirement for antiparkinsonian medications. International Journal of Neuroscience, 74, 191-201.
50. Sandyk, R. & Fisher, H. (1989). Increased incidence neuroleptic-induced movement disorders in pinealectomized rats. International Journal of Neuroscience, 48, 303-308.
51. Sandyk, R. & Derpapas, K. (1993). Further observations on the unique efficacy of picotesla magnetic fields in Parkinson's disease. International Journal of Neuroscience, 69, 167-183.
52. Sandyk, R. & Iacono, R. P. (1993). Reversal of visual neglect in Parkinson's disease by treatment with picotesla range magnetic fields. International Journal of Neuroscience, 73, 93-107.
53. Sandyk, R., Anninos, P. A., Tsagas, N. & Derpapas, K. (1992). Magnetic fields in the treatment of Parkinson's disease. International Journal of Neuroscience, 63, 141-150.
54. Schwab, R. S. & England, A. C. (1969). Projection technique for evaluating surgery in Parkinson's disease. In F. J. Gilligham & M. C. Donaldson (Eds.), Third symposium on parkinson's disease. Edinburgh: E. & S. Livingstone.
55. Semm, P. (1983). Neurobiological investigations on the magnetic sensitivity of the pineal gland in rodents and pigeons. Comparative Biochemistry and Physiology, 76A, 683-689.
56. Semm, P. (1992). Pineal function in mammals and birds is altered by earth-strengh magnetic fields. In M. C. Moore-Ede, S. S. Campbell & R. J. Reiter (Eds.), Electromagnetic fields and circadian rhythmicity (pp. 53-62). Boston: Birkhauser.
57. Shoulson, I., Glaubiger, G. A. & Chase, T. N. (1975). On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology, 25, 1144-1148.
58. Sokol, S. (1980). Visual evoked potentials. In M. J. Aminoff (Ed.), Electrodiagnosis in clinical neurology (pp. 348-369). New York: Churchill Livingstone.
59. Ungerstedt, U. (1971). Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiologica Scandinavica, 397(suppl), 1-48.
60. r tificial magnetic field on serotonin N-acetyltransferase activity and melatonin content of the rat pineal gland. Experimental Brain Research, 50, 426-432.
61. Wilson, B. W., Chess, E. K. & Anderson, L. E. (1986). 60-Hz electric-field effects on pineal melatonin rhythms: time course for onset and recovery. Bioelectromagnetics, 7, 239-242.
62. Wilson, B. W., Stevens, R. G. & Anderson, L. E. (1989). Neuroendocrine mediated effects of electromagnetic field exposure: possible role of the pineal gland. Life Sciences. 45, 1319-1332.
63. Wilson, B. W., Stevens, R. G. & Anderson, L. E. (1992). Effects of electromagnetic field exposure on neuroendocrine function. In M. C. Moore-Ede, S. S. Campbell & R. J. Reiter (Eds.), Electromagnetic fields andcircadian rhythmicity (pp. 29-50). Boston: Birkhauser.
64. Yaar, I. (1980). The effect of levodopa treatment on the visual evoked potentials in parkinsonian patients. Electroencephalography and Clinical Neurophysiology, 50, 267-274.
65. Zisapel, N. & Laudon, M. (1983). Inhibition by melatonin of dopamine release from rat hypothalamus: regulation of calcium entry. Brain research, 272, 378-381.
66. Zisapel, N., Egozi, Y. & Laudon, M. (1982). Inhibition of dopamine release by melatonin: regional distribution in the rat brain. Brain Research. 246, 161-163.
67. Zisapel, N., Egozi, Y. & Laudon, M. (1983). Inhibition by melatonin of dopamine release from rat hypothalamus in vitro: variations with sex and the estrous cycle. Neuroendocrinology, 37, 41-47.
68. Zisapel, N., Egozi, Y. & Laudon, M. (1985). Circadian variations in the inhibition of dopamine release from adult and newborn rat hypothalamus by melatonin. Neuroendocrinology, 40, 102-108.